139 related articles for article (PubMed ID: 37822006)
1. A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive/human epidermal growth factor receptor 2-low expression.
Xin L; Wu Q; Zhan C; Qin H; Xiang H; Gao M; Duan X; Liu Y; Ye J; ;
Chin Med J (Engl); 2023 Dec; 136(24):2967-2973. PubMed ID: 37822006
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021).
Xin L; Wu Q; Zhan C; Qin H; Xiang H; Xu L; Ye J; Duan X; Liu Y;
Chin Med J (Engl); 2022 Mar; 135(6):697-706. PubMed ID: 35274907
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
4. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
6. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (HER2)-low breast cancer: Compared with HER2-0 breast cancer.
Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
[TBL] [Abstract][Full Text] [Related]
7. Multi-center investigation of the clinical and pathological characteristics of inflammatory breast cancer based on Chinese Society of Breast Surgery (CSBrs-007).
Zhou Q; Zhang HP; Zhao YT; Wang XH; Xiong W; Liu YJ; Zhang JH;
Chin Med J (Engl); 2020 Nov; 133(21):2552-2557. PubMed ID: 32925286
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
9. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
11. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Jung HA; Park YH; Kim M; Kim S; Chang WJ; Choi MK; Hong JY; Kim SW; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Tumour Biol; 2015 Feb; 36(2):1073-9. PubMed ID: 25326808
[TBL] [Abstract][Full Text] [Related]
12. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
13. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
14. Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer.
Chen M; Chen W; Liu D; Chen W; Shen K; Wu J; Zhu L
Breast Cancer; 2022 Sep; 29(5):844-853. PubMed ID: 35729304
[TBL] [Abstract][Full Text] [Related]
15. Clinical information and management status of de novo stage IV breast cancer patients: a Chinese multicenter investigation (CSBrS-002).
Zheng A; Guo BL; Zhang JG; Jin F;
Chin Med J (Engl); 2021 Jun; 134(13):1569-1575. PubMed ID: 34101635
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and prognosis of early-stage HER2 low-expression breast cancer: A single-center retrospective study.
Liu CG; Li YF; Ma TY; Lv M; Lv ZD; Wang YY; Liu XP; Mao Y; Wang HB
Front Oncol; 2023; 13():1130734. PubMed ID: 37064133
[TBL] [Abstract][Full Text] [Related]
17. The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A; Plata-Fernández YM; Fernández M; Jaén-Morago A; Fernández-Navarro M; de la Torre-Cabrera C; Ramirez-Tortosa C; Lomas-Garrido M; Llácer C; Navarro-Perez V; Alba-Conejo E; Sánchez-Rovira P
Clin Breast Cancer; 2013 Apr; 13(2):146-52. PubMed ID: 23318089
[TBL] [Abstract][Full Text] [Related]
18. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
[TBL] [Abstract][Full Text] [Related]
20. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]